Rossari Biotech Limited (ROSSARI)

Loading page…

Rossari Biotech Limited (ROSSARI) · mywealthgrid

About

Rossari Biotech operates in specialty chemicals within the materials sector, a segment focused on higher-value, customized chemical solutions. The company has a market capitalization of ₹2,786.62 Cr and reports quarterly revenues in the ₹420–₹700 Cr range. With consistent operating margins of approximately 11–12% and regular dividend payments since 2022, it is positioned as an established, cash-generative player in India's specialty chemicals industry.

Face value: ₹2

Market cap

₹2,369 Cr

P/E

15.7×

P/B

1.8×

Dividend yield

0.1%

ROE

11.8%

ROCE

16%

Debt / equity

0.31

OPM

11.9%

EPS (TTM)

₹27.2

Book value

₹240.7

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Stock underperformance and volatility: 23.48% decline over 1 year and 52-week range of ₹378.6–₹675.05 signal market concerns; verify whether these reflect sector headwinds or company-specific issues.
Institutional investor withdrawal: FII holdings fell from 2.18% to 2.02% and DII from 18.2% to 14.64% between March and June 2026; clarify whether this signals reduced confidence or broader sector rotation.
Thin, cyclical margins: Operating margins of 11–12% limit pricing power and leave little room to absorb input-cost shocks or demand downturns typical in commodity-exposed chemicals.
Valuation premium: PE ratio of 18.49 implies market expectations; verify growth catalysts and compare to historical and peer valuations.

Generated analysis · source review pending

Growth drivers

Operating margins of 11–12% are stable despite quarterly revenue swings of ₹419–₹581 Cr (standalone), indicating cost discipline; sustained volume growth without margin erosion would scale net profit proportionally.
D/E ratio of 0.31 provides financial flexibility; verify whether the company plans capex, R&D, or acquisitions to capture growth opportunities.
Regular dividends (2022–2026) alongside stable margins indicate sustainable cash generation; verify the reinvestment strategy and whether growth is self-funded or capital-constrained.
Specialty chemicals sector exposure in India; verify whether end-markets (pharma, agrochemicals, advanced materials) are growing and whether the company is gaining market share.

Generated analysis · source review pending

1,529 historical price candles were omitted because the exchange source has not been verified.

₹427.6-0%1Y

Quick read

rule-based

Pros

+Revenue CAGR of 27.6% over the last 5 years
+High promoter holding of 68.1% with no pledge

Cons

−Low dividend payout of 1.8% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

60/100

Business quality: 44
Growth: 55
Valuation: 81

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	709	1,483	1,656	1,831	2,080	2,396
COGS	462	1,105	1,171	1,294	1,433	1,669
Gross profit	247	378	485	537	647	728
	124	193	261	287	381	440
	123	185	224	250	266	288
OPM %	17.4%	12.5%	13.5%	13.7%	12.8%	12%
Depreciation	23	48	63	60	67	79
Interest	3	13	22	19	18	29
	9	12	5	7	4	22
Profit before tax	107	136	144	178	185	203
Tax	27	39	37	47	49	53
Tax %	25.1%	28.3%	25.6%	26.4%	26.4%	26.3%
	80	98	107	131	136	149
PAT margin %	11.3%	6.6%	6.5%	7.1%	6.6%	6.2%
EPS (₹)	15.6	17.8	19.5	23.7	24.7	27
EPS adjusted (₹)	15.4	17.7	19.5	23.7	24.6	26.9
	3.2%	2.8%	2.6%	2.1%	2%	1.9%
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	10	10	11	11	11	11	11
Reserves	277	398	794	904	1,037	1,174	1,322
	61	8	43	74	106	188	408
	124	144	408	378	419	523	547
Total equity & liabilities	472	561	1,257	1,368	1,572	1,896	2,289
	89	174	563	584	578	598	784
CWIP	22	0	1	13	47	140	173
Investments	18	36	36	51	63	84	62
	343	351	657	720	885	1,074	1,269
Total assets	472	561	1,257	1,368	1,572	1,896	2,289

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	34.8%	25.5%	29.3%	29.3%	31.1%	30.4%
EBITDA margin %	17.4%	12.4%	13.5%	13.6%	12.7%	11.9%
EBIT margin %	14.1%	9.1%	9.7%	10.3%	9.5%	8.6%
PAT margin %	11.3%	6.6%	6.5%	7.1%	6.6%	6.2%
Working capital
Receivable days	74	75	78	85	83	85
Inventory days	75	63	59	80	90	88
Payable days	12	7	58	62	73	71
NWC days	138	131	79	103	101	103
Leverage
Current ratio	2.36	2.07	2.08	1.99	1.94	1.57
Debt to EBITDA	0.07	0.24	0.33	0.42	0.71	1.43
Debt to equity	0.02	0.05	0.08	0.1	0.16	0.31
Interest coverage	36.6	11.6	7.4	10.2	11.3	8
Asset turnover	1.26	1.18	1.21	1.16	1.1	1.05
Return ratios
Return on assets %	14.3%	7.8%	7.8%	8.3%	7.2%	6.5%
Return on capital employed %	26.6%	21.5%	16.7%	18.2%	16.1%	16%
Return on equity %	19.6%	12.1%	11.7%	12.5%	11.5%	11.2%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	68.35%	68.33%	68.32%	68.32%	68.27%	68.19%	68.18%	68.17%	68.17%	68.16%	68.15%	68.14%
	5.75%	4.14%	4.03%	3.83%	3.74%	3.74%	3.98%	3.48%	2.69%	2.33%	2.18%	2.02%
	17.68%	18.06%	17.75%	16.87%	17.34%	17.47%	17.59%	17.84%	18.18%	18.26%	18.2%	14.64%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	8.22%	9.47%	9.9%	10.98%	10.65%	10.6%	10.25%	10.51%	10.96%	11.25%	11.47%	15.2%
No. of shareholders	—	—	—	—	—	—	—	—	91,387	89,249	86,972	87,580

Promoter holding down 0.21 percentage points since Sep 2023.

1 disclosure

Person	Deal	Shares	Value	Holding	Filed
Jyotishna Sunil ChariPromoter Group	BuyGift	23,00,000	₹141.97 cr	0.30% → 4.45%	30 Aug 20257(2)

Disclosed under SEBI’s insider-trading regulations, which require a filing only above ₹10 lakh in a quarter — smaller dealings are in no disclosure. Holdings are the filer’s own percentages, not recomputed.

5 deals · 20 Sept 2021 – 30 Apr 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
30 Apr 2026	BHUPESH KUMAR LODHA	Bulk	NSE	Buy	2,98,000	₹491.50	₹14.65 Cr
20 Sept 2021	GOLDMAN SACHS INDIA FUND LIMITED	Block	BSE	Sell	6,66,135	₹1,478.65	₹98.50 Cr
20 Sept 2021	GOLDMAN SACHS FUNDS GOLDMAN SACHS INDIA EQUITY PORTFOLIO	Block	BSE	Buy	6,66,135	₹1,478.65	₹98.50 Cr
20 Sept 2021	GOLDMAN SACHS INDIA FUND LIMITED	Bulk	BSE	Sell	6,66,135	₹1,478.65	₹98.50 Cr
20 Sept 2021	GOLDMAN SACHS FUNDS GOLDMAN SACHS INDIA EQUITY PORTFOLIO	Bulk	BSE	Buy	6,66,135	₹1,478.65	₹98.50 Cr

1–5 of 5

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Edward MenezesExecutive Director-Chairperson related to Promoter
Mr. Sunil Srinivasan ChariExecutive Director-MD
Mr. Aseem DhruNon-Executive - Independent Director
Ms. Esha Padmanabhan AchanNon-Executive - Independent Director
Mr. Gurudas Vishwas ArasNon-Executive - Independent Director
Mr. Udeypaul Singh GillNon-Executive - Independent Director
Ms. Manasi NisalChief Financial Officer
Mr. Ketan SablokGroup Chief Financial Officer
Ms. Parul GuptaCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 1 fund houses

Held by these funds

1.07%

of the company's equity

All mutual funds

9.77%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

2 schemes

		Shares
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	5.94 L	28.83	0.35%	1.072%	-1.89 L
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	53	0	0%	0%	-0

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

6

Final dividend10 Jul 2026 · ex-date₹0.5
Final dividend20 Jun 2025 · ex-date₹0.5
Final dividend16 Aug 2024 · ex-date₹0.5
Final dividend24 May 2023 · ex-date₹0.5
Final dividend7 Jul 2022 · ex-date₹0.5
Final dividend8 Sept 2021 · ex-date₹0.5

1

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

93 announcementsExport CSV

16 Sept 2026, 3:08 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

Loading announcements…

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	34.8%	25.5%	29.3%	29.3%	31.1%	30.4%
EBITDA margin %	17.4%	12.4%	13.5%	13.6%	12.7%	11.9%
EBIT margin %	14.1%	9.1%	9.7%	10.3%	9.5%	8.6%
PAT margin %	11.3%	6.6%	6.5%	7.1%	6.6%	6.2%
Working capital
Receivable days	74	75	78	85	83	85
Inventory days	75	63	59	80	90	88
Payable days	12	7	58	62	73	71
NWC days	138	131	79	103	101	103
Leverage
Current ratio	2.36	2.07	2.08	1.99	1.94	1.57
Debt to EBITDA	0.07	0.24	0.33	0.42	0.71	1.43
Debt to equity	0.02	0.05	0.08	0.1	0.16	0.31
Interest coverage	36.6	11.6	7.4	10.2	11.3	8
Asset turnover	1.26	1.18	1.21	1.16	1.1	1.05
Return ratios
Return on assets %	14.3%	7.8%	7.8%	8.3%	7.2%	6.5%
Return on capital employed %	26.6%	21.5%	16.7%	18.2%	16.1%	16%
Return on equity %	19.6%	12.1%	11.7%	12.5%	11.5%	11.2%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Gujarat Fluorochemicals LimitedFLUOROCHEMFLUOROCHEM	₹47,713 Cr	₹49,912 Cr	₹5,303 Cr	₹1,375 Cr	25.8%	₹615 Cr	11.5%	11.1%	7.6%	401
Navin Fluorine International LimitedNAVINFLUORNAVINFLUOR	₹41,740 Cr	₹42,967 Cr	₹3,634 Cr	₹1,232 Cr	32.6%	₹790 Cr	20%	21.6%	20.1%	61
Aether Industries LimitedAETHERAETHER	₹22,161 Cr	₹22,603 Cr	₹1,224 Cr	₹384 Cr	31.3%	₹235 Cr	19.8%	13.2%	9.4%	330
Atul LimitedATULATUL	₹17,231 Cr	₹17,411 Cr	₹6,643 Cr	₹1,189 Cr	16.4%	₹704 Cr	11%	14.1%	11.5%	70
Aarti Industries LimitedAARTIINDAARTIIND	₹16,869 Cr	₹21,790 Cr	₹9,012 Cr	₹1,337 Cr	14.1%	₹531 Cr	5.1%	8.8%	7.3%	54
Fine Organic Industries LimitedFINEORGFINEORG	₹15,752 Cr	₹15,797 Cr	₹2,472 Cr	₹535 Cr	20.4%	₹438 Cr	17.6%	21.6%	16.8%	113
Basf India LimitedBASFBASF	₹14,796 Cr	₹14,796 Cr	₹16,177 Cr	₹952 Cr	4.4%	₹643 Cr	2.8%	14%	11.1%	40
Privi Speciality Chemicals LimitedPRIVISCLPRIVISCL	₹13,970 Cr	₹14,980 Cr	₹2,671 Cr	₹666 Cr	25.2%	₹342 Cr	12.4%	27.7%	25.2%	158
Sudeep Pharma LimitedSUDEEPPHRMSUDEEPPHRM	₹13,546 Cr	₹13,694 Cr	₹676 Cr	₹233 Cr	34.6%	₹133 Cr	27.1%	31.1%	25.2%	366
Anupam Rasayan India LimitedANURASANURAS	₹13,243 Cr	₹15,058 Cr	₹2,535 Cr	₹563 Cr	22.2%	₹175 Cr	9.4%	9.1%	5.5%	377
Vinati Organics LimitedVINATIORGAVINATIORGA	₹12,528 Cr	₹12,528 Cr	₹2,381 Cr	₹665 Cr	29.4%	₹448 Cr	19.9%	18.8%	14.9%	152
Elantas Beck India LimitedELANTASELANTAS	₹10,644 Cr	₹10,644 Cr	₹778 Cr	₹147 Cr	20.3%	₹136 Cr	17.4%	20.6%	15.8%	70

Date	Category	Subject	Filing
16 Sept 2026, 3:08 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
10 Sept 2026, 8:08 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
3 Aug 2026, 7:56 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
24 Jul 2026, 8:31 pm	Company Update Earnings Call Transcript	Announcement under Regulation 30 (LODR)-Earnings Call Transcript	PDF
20 Jul 2026, 10:04 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
20 Jul 2026, 9:51 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
20 Jul 2026, 9:25 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	PDF
20 Jul 2026, 9:08 pm	Company Update General	Update On Grant Of Options.	PDF

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	57	48	29	152	43	137	65
	-190	-37	-299	-181	-103	-184	-219
	157	-25	292	61	16	65	186
Net cash flow	23	-14	22	32	-44	19	32
Free cash flow	—	-10	-9	120	-88	-21	-200
CFO / Operating profit %	—	38.8%	16%	68.3%	17.3%	51.9%	22.8%

Rossari Biotech Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

6

1

Announcements

Not in the F&O segment

Announcements

6

1

Annual reports

Credit ratings

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Rossari Biotech Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Insider dealing

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

Dividends6

Board meetings1

Announcements

Not in the F&O segment

Ratio timeline

Quarterly record

Insider dealing

Bulk & block deals

Board and management

Announcements

Dividends6

Board meetings1

Annual reports

Credit ratings

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

6

1

6

1